AULBIO is a research-intensive biotechnology company located in Korea. It is engaged globally in the research/development and commercialization of highly technical and innovatively formulated brand products based on cutting-edge drug delivery technology (DDT).
Using its proprietary platform technology (Extenna Microsphere Drug Delivery Technology), it is developing long-acting bio-pharmaceutical products that are designed to reduce the number of dosing frequency significantly, resulting in improving the well-being of patients.
We want to position ourselves enthusiastically and optimistically as a leading innovator in the global biopharmaceutical market, today and for the future.
Using its proprietary platform technology (Extenna Microsphere Drug Delivery Technology), it is developing long-acting bio-pharmaceutical products that are designed to reduce the number of dosing frequency significantly, resulting in improving the well-being of patients.
We want to position ourselves enthusiastically and optimistically as a leading innovator in the global biopharmaceutical market, today and for the future.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Korea - South Korea
Year Founded:
February 01, 2018
Main Therapeutic Focus:
Cardiovascular
Lead Product in Development:
Tirzepatide monthly inj., Semaglutide monthly inj.
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
10
Speaker
